Sino Biopharmaceutical Statistics
Total Valuation
FRA:SMZ1 has a market cap or net worth of EUR 7.93 billion. The enterprise value is 8.63 billion.
Market Cap | 7.93B |
Enterprise Value | 8.63B |
Important Dates
The next estimated earnings date is Friday, May 16, 2025.
Earnings Date | May 16, 2025 |
Ex-Dividend Date | Jun 16, 2025 |
Share Statistics
Current Share Class | 17.89B |
Shares Outstanding | n/a |
Shares Change (YoY) | -2.36% |
Shares Change (QoQ) | -1.25% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 8.85B |
Valuation Ratios
The trailing PE ratio is 17.12 and the forward PE ratio is 19.20.
PE Ratio | 17.12 |
Forward PE | 19.20 |
PS Ratio | 2.08 |
PB Ratio | 1.40 |
P/TBV Ratio | 1.95 |
P/FCF Ratio | 10.60 |
P/OCF Ratio | 9.06 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 10.25, with an EV/FCF ratio of 11.53.
EV / Earnings | 18.64 |
EV / Sales | 2.43 |
EV / EBITDA | 10.25 |
EV / EBIT | 12.37 |
EV / FCF | 11.53 |
Financial Position
The company has a current ratio of 1.26, with a Debt / Equity ratio of 0.23.
Current Ratio | 1.26 |
Quick Ratio | 1.11 |
Debt / Equity | 0.23 |
Debt / EBITDA | 1.39 |
Debt / FCF | 1.72 |
Interest Coverage | 19.66 |
Financial Efficiency
Return on equity (ROE) is 11.82% and return on invested capital (ROIC) is 7.02%.
Return on Equity (ROE) | 11.82% |
Return on Assets (ROA) | 5.62% |
Return on Invested Capital (ROIC) | 7.02% |
Return on Capital Employed (ROCE) | 12.65% |
Revenue Per Employee | 156,688 |
Profits Per Employee | 18,997 |
Employee Count | 24,379 |
Asset Turnover | 0.45 |
Inventory Turnover | 2.44 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +20.62% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | +20.62% |
50-Day Moving Average | 0.42 |
200-Day Moving Average | 0.39 |
Relative Strength Index (RSI) | 54.41 |
Average Volume (20 Days) | 31,083 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, FRA:SMZ1 had revenue of EUR 3.82 billion and earned 463.14 million in profits. Earnings per share was 0.03.
Revenue | 3.82B |
Gross Profit | 3.11B |
Operating Income | 767.68M |
Pretax Income | 698.37M |
Net Income | 463.14M |
EBITDA | 912.13M |
EBIT | 767.68M |
Earnings Per Share (EPS) | 0.03 |
Balance Sheet
The company has 1.96 billion in cash and 1.29 billion in debt, giving a net cash position of 675.86 million.
Cash & Cash Equivalents | 1.96B |
Total Debt | 1.29B |
Net Cash | 675.86M |
Net Cash Per Share | n/a |
Equity (Book Value) | 5.66B |
Book Value Per Share | 0.24 |
Working Capital | 678.71M |
Cash Flow
In the last 12 months, operating cash flow was 875.39 million and capital expenditures -127.05 million, giving a free cash flow of 748.34 million.
Operating Cash Flow | 875.39M |
Capital Expenditures | -127.05M |
Free Cash Flow | 748.34M |
FCF Per Share | n/a |
Margins
Gross margin is 81.51%, with operating and profit margins of 20.10% and 12.12%.
Gross Margin | 81.51% |
Operating Margin | 20.10% |
Pretax Margin | 18.28% |
Profit Margin | 12.12% |
EBITDA Margin | 23.88% |
EBIT Margin | 20.10% |
FCF Margin | 19.59% |
Dividends & Yields
This stock pays an annual dividend of 0.01, which amounts to a dividend yield of 1.61%.
Dividend Per Share | 0.01 |
Dividend Yield | 1.61% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 52.76% |
Buyback Yield | 2.36% |
Shareholder Yield | 3.97% |
Earnings Yield | 5.84% |
FCF Yield | 9.44% |
Stock Splits
The last stock split was on July 20, 2020. It was a forward split with a ratio of 1.5.
Last Split Date | Jul 20, 2020 |
Split Type | Forward |
Split Ratio | 1.5 |
Scores
FRA:SMZ1 has an Altman Z-Score of 2.75. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 2.75 |
Piotroski F-Score | n/a |